JPH0314808B2 - - Google Patents
Info
- Publication number
- JPH0314808B2 JPH0314808B2 JP62012184A JP1218487A JPH0314808B2 JP H0314808 B2 JPH0314808 B2 JP H0314808B2 JP 62012184 A JP62012184 A JP 62012184A JP 1218487 A JP1218487 A JP 1218487A JP H0314808 B2 JPH0314808 B2 JP H0314808B2
- Authority
- JP
- Japan
- Prior art keywords
- antihypertensive agent
- formula
- solution
- value
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000243 solution Substances 0.000 claims description 26
- 239000002220 antihypertensive agent Substances 0.000 claims description 18
- 229940030600 antihypertensive agent Drugs 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000010253 intravenous injection Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004327 boric acid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001767 cationic compounds Chemical class 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 229910001411 inorganic cation Inorganic materials 0.000 claims description 3
- 150000002892 organic cations Chemical class 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- VWZUIIYOJGQRBR-UHFFFAOYSA-N 2-(3,4-dihydroxyanilino)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)NC1=CC=C(O)C(O)=C1 VWZUIIYOJGQRBR-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- -1 for example Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU86268A HU195424B (en) | 1986-01-21 | 1986-01-21 | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine |
| HU2251/268/86 | 1986-01-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62228013A JPS62228013A (ja) | 1987-10-06 |
| JPH0314808B2 true JPH0314808B2 (ko) | 1991-02-27 |
Family
ID=10948826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62012184A Granted JPS62228013A (ja) | 1986-01-21 | 1987-01-21 | 血圧降下剤およびその製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS62228013A (ko) |
| AT (1) | AT389227B (ko) |
| DE (1) | DE3701461A1 (ko) |
| FR (1) | FR2597341B1 (ko) |
| GB (1) | GB2185975B (ko) |
| HU (1) | HU195424B (ko) |
| IT (1) | IT1201174B (ko) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL263355A (ko) * | 1960-04-08 | |||
| US3526698A (en) * | 1968-04-11 | 1970-09-01 | Merck & Co Inc | Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol |
| CH552567A (de) * | 1970-10-30 | 1974-08-15 | Hoffmann La Roche | Verfahren zur herstellung von phenylalaninderivaten. |
| CH545280A (de) * | 1970-10-30 | 1973-12-15 | Hoffmann La Roche | Verfahren zur Herstellung von Phenylalaninderivaten |
-
1986
- 1986-01-21 HU HU86268A patent/HU195424B/hu not_active IP Right Cessation
-
1987
- 1987-01-20 DE DE19873701461 patent/DE3701461A1/de active Granted
- 1987-01-21 FR FR878700637A patent/FR2597341B1/fr not_active Expired
- 1987-01-21 IT IT19118/87A patent/IT1201174B/it active
- 1987-01-21 AT AT0010587A patent/AT389227B/de not_active IP Right Cessation
- 1987-01-21 GB GB8701281A patent/GB2185975B/en not_active Expired - Lifetime
- 1987-01-21 JP JP62012184A patent/JPS62228013A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT8719118A0 (it) | 1987-01-21 |
| IT1201174B (it) | 1989-01-27 |
| GB2185975B (en) | 1990-03-21 |
| DE3701461C2 (ko) | 1992-06-04 |
| FR2597341A1 (fr) | 1987-10-23 |
| FR2597341B1 (fr) | 1989-05-12 |
| DE3701461A1 (de) | 1987-07-23 |
| AT389227B (de) | 1989-11-10 |
| ATA10587A (de) | 1989-04-15 |
| HU195424B (en) | 1988-05-30 |
| HUT42947A (en) | 1987-09-28 |
| GB2185975A (en) | 1987-08-05 |
| JPS62228013A (ja) | 1987-10-06 |
| GB8701281D0 (en) | 1987-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5589491A (en) | Injection and injection kit containing omeprazole and its analogs | |
| CA1052270A (en) | Oxytetracycline solution for parenteral peroral and local administration and processes for the production thereof | |
| KR20070027719A (ko) | 고혈압 치료를 위한 약제학적 조성물 | |
| PT96400B (pt) | Processo de preparacao de composicoes farmaceuticas a base de complexos de acido quinolona-carboxilico-iao metalico-acido | |
| JP2950840B2 (ja) | クエン酸鉄−ミセル錯体、その製法および鉄欠乏性貧血の治療剤 | |
| JP2526059B2 (ja) | 抗潰瘍剤 | |
| EP0233615B1 (en) | Aqueous preparation and method of preparation thereof | |
| WO2002055107A1 (fr) | Compositions anesthesiques topiques | |
| JP2563336B2 (ja) | 角膜透過促進点眼剤 | |
| JPH02326B2 (ko) | ||
| JPH0314808B2 (ko) | ||
| CA2416600A1 (en) | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof | |
| RU2053766C1 (ru) | Фармацевтическая композиция, ингибирующая рост опухоли | |
| US5084276A (en) | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation | |
| EP0365363B1 (en) | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | |
| JP3694868B2 (ja) | ヒアルロン酸ナトリウム注射液組成物 | |
| GB2143732A (en) | Homocarnosine for antitumor formulation | |
| JP3280726B2 (ja) | 抗潰瘍剤 | |
| EP1685837A1 (en) | Percutaneous absorption type cerebral protective agent | |
| JPS59508B2 (ja) | ノウケツカンカクチヨウザイ ２ ３− チカン −４− フクソカンジヨウアミノスルホニルベンゼンスルホンアミド ノ セイホウ | |
| JPH0366617A (ja) | 静脈内投与用フエニトインナトリウム製剤 | |
| EP0115331B1 (en) | Medicament for cerebral apoplexy | |
| CA2505139C (en) | Oromucosal formulation and process for preparing the same | |
| JPH08291075A (ja) | 癌転移阻害剤 | |
| NZ206523A (en) | Anti-thrombotic pharmaceutical compositions comprising a hydrogenated ergot alkaloid and a low molecular weight heparin |